UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month ofMay, 2020
Commission File Number:333-229744
EMERALD HEALTH THERAPEUTICS, INC.
(Name of registrant)
210 - 800 West Pender Street
Vancouver, British Columbia V6C 1J8
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
[ X ] Form 20-F [ ] Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
Form 6-K Exhibit Index
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Emerald Health Therapeutics, Inc. | ||
Date: May 13, 2020 | By: | /s/ Avtar Dhillon |
Name: Avtar Dhillon, MD | ||
Title: Executive Chairman, Principal Executive Officer |